Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 8/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 8/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.41 |
| ▸ | CHRNB3 | Q05901 | 8/20 | 0.41 |
| ▸ | CHRNA6 | Q15825 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178766 | 0.89 | HSD11B1 (0.33) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL21158713 | 0.83 | CHRNB2 (0.40) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL23073865 | 0.77 | MEN1 (0.31) | ALDH1A1 | |
| SCHEMBL19251516 | 0.77 | CHRNB2 (0.38) | CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL20118843 | 0.76 | — | — | |
| SCHEMBL10188198 | 0.75 | CHRNB2 (0.41) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL20626234 | 0.75 | CHRNB2 (0.38) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL23896448 | 0.73 | PIK3CD (0.33) | — | |
| SCHEMBL26712850 | 0.72 | HSD11B1 (0.32) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL22752636 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210186959-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2021-06-24 | — | — | US | disclosed |
| US-10555944-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ELI LILLY AND COMPANY (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190183886-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2019-06-20 | — | — | US | disclosed |
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10555944-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | CHRNB2 2276/4885CHRNA3 1700/4885CHRNA4 1977/4885 |
| US-20190183886-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | CHRNB2 2276/4885CHRNA3 1700/4885CHRNA4 1977/4885 |
| US-20210186959-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | CHRNB2 2276/4885CHRNA3 1700/4885CHRNA4 1977/4885 |
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | CHRNB2 2276/4885CHRNA3 1700/4885CHRNA4 1977/4885 |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | CHRNB2 2276/4885CHRNA3 1700/4885CHRNA4 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.